Ocular effects of oral contraceptives. II. Studies in the rhesus monkey.
Oral contraceptives were administered cyclically to 96 female rhesus monkeys for 5 years. Forty-eight animals received Enovid-E and 48 were treated with Ovulen at doses 1, 10, and 50 times the human dose. Ophthalmic lesions did not occur at any of the dose levels employed. Significant fundic lesions, including papilledema, venous dilatation, venous retinal thrombosis, or arterial retinal thrombosis, did not develop in any of the treated animals.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects* / Q000494:pharmacology; D005040:Ethynodiol Diacetate / Q000494:pharmacology; D005123:Eye / Q000187:drug effects*; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D005654:Fundus Oculi / Q000187:drug effects; D000882:Haplorhini; D008253:Macaca mulatta; D008598:Menstruation / Q000187:drug effects; D008656:Mestranol / Q000494:pharmacology; D009026:Mortality; D009641:Norethynodrel / Q000494:pharmacology
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D005040:Ethynodiol Diacetate; D009641:Norethynodrel; D008656:Mestranol